Cargando…
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL
TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) is a promising novel anticancer agent that selectively induces apoptosis in tumour cells and the activity of which can be enhanced by combined treatment with chemo- or radiotherapy. For therapeutic purposes, the use of full-length T...
Autores principales: | Abou El Hassan, M A I, Mastenbroek, D C J, Gerritsen, W R, Giaccone, G, Kruyt, F A E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364740/ https://www.ncbi.nlm.nih.gov/pubmed/15173860 http://dx.doi.org/10.1038/sj.bjc.6601910 |
Ejemplares similares
-
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas
por: Kelly, J D, et al.
Publicado: (2004) -
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
por: de Graaff, Marieke A, et al.
Publicado: (2016) -
Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007) -
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt
por: Szegezdi, E, et al.
Publicado: (2006) -
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)